The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register
Open accessAbstract
Objective: Rheumatoid arthritis (RA) is associated with an increased risk of coronary artery disease, possibly acting via shared mechanisms of inflammation. This study was undertaken to test the hypothesis that the powerful antiinflammatory effect of anti–tumor necrosis α (anti‐TNFα) therapy might lead to a reduction in the incidence of myocardial infarction (MI) in patients with RA. Methods: Using data from the British Society for Rheumatology Biologics Register, a national prospective observational study, we compared MI rates in 8,670 patients with RA treated with anti‐TNFα and 2,170 patients with active RA treated with traditional disease‐modifying antirheumatic drugs (DMARDs). Results: Through July 2006, 63 MIs occurred in the anti‐TNFα cohort during 13,233 person‐years of followup and 17 MIs occurred in the DMARD cohort during 2,893 person‐years of followup, equivalent to a rate of 4.8 events per 1,000 person‐years and 5.9 events per 1,000 person‐years, respectively. After adjustment for baseline risk factors, there was no reduction in the rate of MI in the anti‐TNFα cohort compared with the DMARD cohort (incidence rate ratio 1.44 [95% confidence interval 0.56–3.67]). In an analysis of anti‐TNFα–treated patients who responded to the treatment within 6 months versus those who did not, MI rates were found to be 3.5 events per 1,000 person‐years in responders and 9.4 events per 1,000 person‐years in nonresponders. The adjusted incidence rate ratio (95% confidence interval) for responders compared with nonresponders was 0.36 (0.19–0.69). Conclusion: These results indicate that RA patients treated with anti‐TNFα do not have a lower incidence of MI compared with RA patients treated with traditional DMARDs. However, the risk of MI is markedly reduced in those who respond to anti‐TNFα therapy by 6 months compared with nonresponders. This finding supports the notion that inflammation plays a pivotal role in MI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Elevated Circulating Levels of Tumor Necrosis Factor in Severe Chronic Heart Failure
Levine, B., Kalman, J., Mayer, L., Fillit, H. M., & Packer, M. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007263230405 · Cited by 2,582 · cited 1×
“Raised levels of TNF in chronic heart failure (28), along with the predictive value of high levels of TNF on adverse outcome in chronic heart failure (29), led to studies to explore the potential benefit of anti-TNF therapy in severe chronic heart failure.”
BackgroundChung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A., & Willerson, J. T. (2003) · Circulation · doi:10.1161/01.cir.0000077913.60364.d2 · Cited by 1,644
Townsend, P. (1987) · Journal of Social Policy · doi:10.1017/s0047279400020341 · Cited by 1,294
Plasma Cytokine Parameters and Mortality in Patients With Chronic Heart Failure
Rauchhaus, M., Doehner, W., Francis, D. P., Davos, C., Kemp, M., Liebenthal, C., Niebauer, J., Hooper, J., Volk, H.-D., Coats, A. J. S., et al. (2000) · Circulation · doi:10.1161/01.cir.102.25.3060 · Cited by 810
Cited by
The immune system in atherosclerosis
Hansson, G. K., & Hermansson, A. (2011) · Nature Immunology · doi:10.1038/ni.2001 · Cited by 2,317
Peters, M. J. L., Symmons, D. P. M., McCarey, D., Dijkmans, B. A. C., Nicola, P., Kvien, T. K., McInnes, I. B., Haentzschel, H., Gonzalez-Gay, M. A., Provan, S., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.113696 · Cited by 1,325
Self-citationEmery, P., Keystone, E., Tony, H. P., Cantagrel, A., van Vollenhoven, R., Sanchez, A., Alecock, E., Lee, J., & Kremer, J. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092932 · Cited by 1,104
Roubille, C., Richer, V., Starnino, T., McCourt, C., McFarlane, A., Fleming, P., Siu, S., Kraft, J., Lynde, C., Pope, J., et al. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206624 · Cited by 907
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Metadata
- Authors
- Dixon, W. G., Watson, K. D., Lunt, M., Hyrich, K. L., Silman, A. J., & Symmons, D. P. M.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2007-08-30
- Volume
- 56
- Issue
- 9
- Pages
- 2905-2912
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2075619622
- Cited by
- 562
- References
- 6
- FWCI
- 27.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register. https://app.cochat.ai/papers/10.1002/art.22809
- The paper
- Dixon, W. G., Watson, K. D., Lunt, M., Hyrich, K. L., Silman, A. J., & Symmons, D. P. M. (2007). Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register. Arthritis & Rheumatism. https://doi.org/10.1002/art.22809
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
